01861-A: Preventing Heart Damage during Chemotherapy through Early Detection of Cardiotoxicity
Grant Status: Closed
Grant Amount: $12,960
Leigh G. Griffiths, DVM; University of California, Davis
August 1, 2012 - April 30, 2014
Sponsor(s):
Breed(s): -All Dogs
Research Program Area: Oncology
Donate to Support this Research Program Area
Abstract
Doxorubicin is a commonly used chemotheraputic agent in veterinary oncology with efficacy in the treatment of many cancer types. It has been well documented that doxorubicin can cause toxic changes to the heart that can result in heart failure and even death. Abnormal heart rhythms can also occur, however in veterinary medicine, the extent of these abnormal heart rhythms has not been well documented. The purpose of this study is to evaluate the effect of doxorubicin on the occurrence of abnormal heart rhythms. The study additionally aims to evaluate the use of a biomarker for heart damage (cardiac Troponin I), as a measure of early heart muscle damage due to Doxorubicin toxicity and to determine whether serum level of this biomarker are correlated with early changes in heart function.Publication(s)
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
